Preclinical study of safety and neuroprotective efficacy of intranasal NEUROSTAT-NP in a rat model of chronic glaucoma

Journal Of Advanced Pharmacy Education And Research 2026 Open access

Read full text
Authors: Melavinka Agubechirovna Sozaeva, Arina Arturovna Sargsyan, Dzhabrail Magomedovich Gaziev, Kerim Alimovich Magaramov, Faina Taubievna Dyshekova, Aina Aslanovna Mezhidova, Alibek Aslanovich Kodzokov, Tengiz Maratovich Mollaev, Tamerlan Albertovich Pliev, Akhmad Zurabovich Chertkoev
DOI: 10.51847/thypbfsld9
Cited by: 0
References: 75

Abstract

Glaucoma is the main cause of irreversible blindness. Despite reaching the target level of intraocular pressure (IOP), glaucoma often progresses. This highlights the urgent need for therapy aimed directly at protecting the optic nerve. This study presents the development and comprehensive preclinical evaluation of a novel drug, NEUROSTAT-NP – a dry intranasal powder for direct neuroprotection. The active ingredient, bromocriptine mesylate at an ultra-low dose of 0.3 mg, selectively activates dop

Fields of Study & Subjects

Glaucoma and retinal disorders Advanced Drug Delivery Systems Neuroprotection in Cerebral Ischemia

Publication details

Journal / source
Journal Of Advanced Pharmacy Education And Research
Volume
16
Issue
1
Pages
115–126
Publication date
1 January 2026
Language
EN